A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 10 Dec 2018
At a glance
- Drugs IMX-110 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Immix Biopharma Australia
- 10 Dec 2018 According to an Immix Biopharma media release, the company is awaiting additional preliminary efficacy readouts from patients in cohorts (dose-levels) 3 and 4 after which recruitment in cohort 5 will be initiated.
- 06 Aug 2018 According to an Immix Biopharma media release, first two patients have been dosed in this trial.
- 27 Feb 2018 Status changed from not yet recruiting to recruiting.